Skip to main content
Premium Trial:

Request an Annual Quote

Life Tech Ion AmpliSeq Exome CSP Program Names Seven Initial Members

NEW YORK (GenomeWeb News) – Life Technologies today announced the Ion AmpliSeq Exome Certified Service Provider program and its first members.

The program is part of the Ion Certified Service Provider program and provides its members access to the Ion AmpliSeq Exome Kit, the Ion Proton Sequencer, and Ion Reporter Software, allowing two exomes to be sequenced in one run and results from DNA to be attained in two days, according to the firm.

Life Tech said that the Ion AmpliSeq Exome Kit delivers up to 98 percent base coverage at 10x and up to 95 percent base coverage at 20x for a single exome, and added that the Ion Reporter Software provides a list of mutations drawn from multiple public databases within hours of a sequencing run. The software enables researchers to access their data through the web "and rich filtering tools that help them focus on the most impactful variants," the Carlsbad, Calif.-based company said.

The initial members of the certified service program are the Hospital for Sick Children; Memorial Sloan Kettering Cancer Center; Claritas Genomics; Roswell Park Cancer Institute; GeneDx; Cedars Sinai Genomics Core; and Selah Genomics. Additional members will be named shortly, Life Tech said.

In a statement, Candace Johnson, deputy director and the Wallace Chair of Translational Research at Roswell Park, said that exome sequencing will be crucial to discoveries made in clinical research. Noting that the Ion AmpliSeq Exome Certified Service Provider program requires as little as 50 ng of input material, she said it "enables researchers to get access to high-quality exome sequencing data from small amounts of input material … and with very fast turnaround. Generating vast amounts of genomic data helps us and others understand the mechanisms of how cancer develops and spreads."

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.